LKT Labs

Biochemicals for Life Science Research

Cyclovirobuxine D

Cyclovirobuxine D

Product ID C9711
Cas No. 860-79-7
Purity ≥97%
Product Unit SizeCostQuantityStock
25 mg $128.00 In stock
100 mg $318.00 In stock
500 mg $1,086.00 In stock
Bulk Quote

Quicklinks

Description

Cyclovirobuxine D is originally found in Buxus and displays cardioprotective and anticancer activities. Cyclovirobuxine inhibits the viability of breast cancer cells, inhibiting phosphorylation of Akt and mTOR and inducing autophagy. This compound also shows benefit in the treatment of heart failure but may prolong the QT interval through inhibition of human ether-a-go-go-related (hERG) K+ channel currents. Additionally, cyclovirobuxine D decreases infarct size and venous thrombus size in animal models of myocardial ischemia.

Product Info

Cas No.

860-79-7
Purity

≥97%
Formula

C26H46N2O
Formula Wt.

402.66
IUPAC Name

C26H46N2O
Synonym

Bebuxine, Cyclovirobuxine
Melting Point

219-224°C
Appearance

White crystal

Shipping and Storage

Store Temp

4°C
Ship Temp

Ambient

Downloads

MSDS

C9711 MSDS PDF
Info Sheet

C9711 Info Sheet PDF

References

Lu J, Sun D, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. PMID: 24758922.

Yu B, Fang TH, Lü GH, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. PMID: 21575690.

Zhao J, Wang Q, Xu J, et al. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells. Eur J Pharmacol. 2011 Jun 25;660(2-3):259-67. PMID: 21497594.

Hu D, Liu X, Wang Y, et al. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9. PMID: 17555743.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • O2146

    R-(+)-Ofloxacin

    Fluoroquinolone, optically active isomer of ofl...

    ≥98%
  • B1752

    Benidipine Hydrochloride

    Calcium channel blocker.

    ≥98%
  • C8500

    CV-65

    1,8-Diaza-anthracene-tetrone; JNK and ERK5 inhi...

    ≥70%
  • F4420

    Boc-FLFLF

    Peptide; FRP1 antagonist.

    ≥95%
  • B3203

    Biapenem

    β-lactam; penicillin binding protein inhibitor...

    ≥98%
  • P6855

    (±)-S-Propyl-L-cysteine-S-oxide

    Organosulfur found in Allium; analog of alliin....

    ≥98%
  • D5709

    Docetaxel

    Semi-synthetic analog of taxol; microtubule dep...

    ≥98%
  • A7071

    Atriopeptin II, rat/rabbit/mouse

    ANP analog, cardiomodulatory peptide; NPR-A ago...

    ≥95%
  • C9608

    Cycloastragenol

    Triterpene aglycone found in Radix Astragali; t...

    ≥98%
  • I7155

    Isoindigo

    Potential AhR binding agent.

    ≥98%
  • E6397

    EPZ6438

    Potent and selective inhibitor

    ≥98%
  • C5773

    Cortistatin-14

    Endogenous neuropeptide, somatostatin analog; s...

    ≥95%
  • T5608

    α-Tocotrienol

    Antioxidant, vitamin E derivative found in vege...

    ≥98%
  • B4514

    Bleomycin A5 Hydrochloride Cu

    Induces apoptosis, DNA cleavage and strand brea...

    ≥85%
  • P7034

    Prion Peptide (106-126), human

    Synthetic peptide fragment, prion protein analo...

    ≥95%
  • R1985

    Reveromycin A

    Isoleucyl-tRNA synthase inhibitor, osteoclast p...

    ≥98%
  • M1685

    Mevastatin

    Statin; HMG-CoA reductase inhibitor.

    ≥98%
  • P2002

    PF-04691502 Dihydrate

    PI3K and mTOR inhibitor.

    ≥98%
  • A4777

    Altiratinib

    c-MET, Tie-2, VEGFR inhibitor.

    ≥98%
  • L1780

    Levocetirizine Dihydrochloride

    L-isomer of cetirizine; histamine H1 antagonist...

    ≥98%